Targeting SUMOylation in Combination with Agonistic Anti-CD40 Therapy Activates Anti- Tumor Immunity to Control Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive, lethal form of cancer and available immunotherapies are ineffective for most patients. In this study, we investigated combining agonistic anti-CD40 (aCD40) with TAK-981 (TAK/subasumstat), a SUMOylation inhibitor with immune priming effects. We previously reported that TAK-981 increases CD40 expression on antigen-presenting cells, and thus we hypothesized that combining it with an agonistic CD40 antibody (aCD40) would enhance immune-mediated tumor control. We investigated the therapeutic effect of TAK-981 + aCD40 in vivo using three syngeneic, orthotopic mouse models of PDAC. Single-cell RNA sequencing, flow cytometry, and immunofluorescence/immunohistochemistry were used to identify immunogenic changes in the tumor microenvironment. T-cell and macrophage depletions were used to assess functional contributions of individual immune cell populations. We assessed the functional contributions of T-cells and macrophages by depleting their populations separately.TAK-981+aCD40 treatment augmented CD8+ T-cell and macrophage infiltration into the tumor, amplified IFNα and IFNγ signaling, decreased TGFβ signaling and increased MHC-I expression resulting in decreased tumor burden and improved median survival. Despite the induction of dramatic CD8+ T cell infiltration into tumors, the efficacy of combination therapy was not impacted by T cell deficiency or depletion. In contrast, depletion of phagocytic macrophages abolished the therapeutic benefit of combination therapy. Therefore, TAK-981+aCD40 combination therapy activates macrophage mediated anti-tumor immunity in the PDAC models. Our findings support further exploration of this combination in clinical trials to validate this combination as a strategy to generate meaningful macrophage-mediated anti-tumor immune responses in pancreatic cancer patients.

Authors

Institutions

Publication Details

Journal
Molecular Cancer Therapeutics
Published
2026-11-17
DOI
https://doi.org/10.1158/1535-7163.mct-25-1540
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting SUMOylation in Combination with Agonistic Anti-CD40 Therapy Activates Anti- Tumor Immunity to Control Pancreatic Cancer

Tatiana Hurtado de Mendoza, Yuan Chen, Hervé Tiriac, M.D. Neranjan Tharuka et al.
7 links
Molecular Cancer Therapeutics
Cancer Immunotherapy and Biomarkers
article

Targeting SUMOylation in Combination with Agonistic Anti-CD40 Therapy Activates Anti- Tumor Immunity to Control Pancreatic Cancer

Tatiana Hurtado de Mendoza, Yuan Chen, Hervé Tiriac, M.D. Neranjan Tharuka, Alexei Martsinkovskiy, Evangeline Sari. Mose, Mia MacDonald, Bharti Garg, Kevin Li, Siming Sun, Ponmathi Panneerpandian, Karen S. Messer, James Lee, Andrew M. Lowy, Jay Patel, Rithika Medari, Jiayu Chen, Isabella Ng, Asimina S. Courelli, Catarina da Silva Maia
article en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive, lethal form of cancer and available immunotherapies are ineffective for most patients. In this study, we investigated combining agonistic anti-CD40 (aCD40) with TAK-981 (TAK/subasumstat), a SUMOylation inhibitor with immune priming effects. We previously reported that TAK-981 increases CD40 expression on antigen-presenting cells, and thus we hypothesized that combining it with an agonistic CD40 antibody (aCD40) would enhance immune-mediated tumor control. We investigated the therapeutic effect of TAK-981 + aCD40 in vivo using three syngeneic, orthotopic mouse models of PDAC. Single-cell RNA sequencing, flow cytometry, and immunofluorescence/immunohistochemistry were used to identify immunogenic changes in the tumor microenvironment. T-cell and macrophage depletions were used to assess functional contributions of individual immune cell populations. We assessed the functional contributions of T-cells and macrophages by depleting their populations separately.TAK-981+aCD40 treatment augmented CD8+ T-cell and macrophage infiltration into the tumor, amplified IFNα and IFNγ signaling, decreased TGFβ signaling and increased MHC-I expression resulting in decreased tumor burden and improved median survival. Despite the induction of dramatic CD8+ T cell infiltration into tumors, the efficacy of combination therapy was not impacted by T cell deficiency or depletion. In contrast, depletion of phagocytic macrophages abolished the therapeutic benefit of combination therapy. Therefore, TAK-981+aCD40 combination therapy activates macrophage mediated anti-tumor immunity in the PDAC models. Our findings support further exploration of this combination in clinical trials to validate this combination as a strategy to generate meaningful macrophage-mediated anti-tumor immune responses in pancreatic cancer patients.

Molecular Cancer Therapeutics
University of San Diego (US), UC San Diego Health System (US), University of California San Diego (US), Moores Cancer Center (US)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon